Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation

被引：5

作者：

Zettl, Uwe Klaus ^{[1
,10
]}

Rommer, Paulus Stefan ^{[1
,2
]}

Aktas, Orhan ^{[3
]}

Wagner, Torsten ^{[4
]}

Richter, Joachim ^{[4
]}

Oschmann, Patrick ^{[5
]}

Cepek, Lukas ^{[6
]}

Elias-Hamp, Birte ^{[7
]}

Gehring, Klaus ^{[8
]}

Chan, Andrew ^{[9
]}

Hecker, Michael ^{[1
]}

机构：

[1] Rostock Univ, Med Ctr, Dept Neurol, Rostock, Germany

[2] Med Univ Vienna, Dept Neurol, Vienna, Austria

[3] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany

[4] Merck Healthcare Germany GmbH, Weiterstadt, Germany

[5] Bayreuth Hosp, Dept Neurol, Bayreuth, Germany

[6] Neurol Grp Practice, Ulm, Germany

[7] Neurol Private Practice, Hamburg, Germany

[8] Neuroctr Itzehoe, Itzehoe, Germany

[9] Univ Hosp Bern, Dept Neurol, Inselspital Bern, Bern, Switzerland

[10] Rostock Univ, Med Ctr, Dept Neurol, Div Neuroimmunol, Gehlsheimer Str 20, D-18147 Rostock, Germany

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2023年 / 19卷 / 11期

关键词：

Interferon beta-1a; multiple sclerosis; disease-modifying therapy; 25; years; generation; long-term efficacy; long-term safety; mechanisms of action; DISEASE-MODIFYING THERAPIES; MEMORY B-CELLS; RESOURCE UTILIZATION; GENE-EXPRESSION; DOUBLE-BLIND; IFN-BETA; ADHERENCE; MULTICENTER; TERM; ALEMTUZUMAB;

D O I：

10.1080/1744666X.2023.2248391

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionInterferon beta (IFN beta) preparations are an established group of drugs used for immunomodulation in patients with multiple sclerosis (MS). Subcutaneously (sc) applied interferon beta-1a (IFN beta-1a sc) has been in continuous clinical use for 25 years as a disease-modifying treatment.Areas coveredBased on data published since 2018, we discuss recent insights from analyses of the pivotal trial PRISMS and its long-term extension as well as from newer randomized studies with IFN beta-1a sc as the reference treatment, the use of IFN beta-1a sc across the patient life span and as a bridging therapy, recent data regarding the mechanisms of action, and potential benefits of IFN beta-1a sc regarding vaccine responses.Expert opinionIFN beta-1a sc paved the way to effective immunomodulatory treatment of MS, enabled meaningful insights into the disease process, and remains a valid therapeutic option in selected vulnerable MS patient groups.

引用

页码：1343 / 1359

页数：17

共 192 条

[1] cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING [J].

Ablasser, Andrea ;

Goldeck, Marion ;

Cavlar, Taner ;

Deimling, Tobias ;

Witte, Gregor ;

Roehl, Ingo ;

Hopfner, Karl-Peter ;

Ludwig, Janos ;

Hornung, Veit .

NATURE, 2013, 498 (7454) :380-+

[2] Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis [J].

Abrahamyan, Sargis ;

Eberspaecher, Bettina ;

Hoshi, Muna-Miriam ;

Aly, Lilian ;

Luessi, Felix ;

Groppa, Sergiu ;

Klotz, Luisa ;

Meuth, Sven G. ;

Schroeder, Christoph ;

Grueter, Thomas ;

Tackenberg, Bjoern ;

Paul, Friedemann ;

Then-Bergh, Florian ;

Kuempfel, Tania ;

Weber, Frank ;

Stangel, Martin ;

Bayas, Antonios ;

Wildemann, Brigitte ;

Heesen, Christoph ;

Zettl, Uwe ;

Warnke, Clemens ;

Antony, Gisela ;

Hessler, Nicole ;

Wiendl, Heinz ;

Bittner, Stefan ;

Hemmer, Bernhard ;

Gold, Ralf ;

Salmen, Anke ;

Ruprecht, Klemens .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (07) :681-686

[3] Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment [J].

Aliaga-Gaspar, Pablo ;

Hurtado-Guerrero, Isaac ;

Ciano-Petersen, Nicolas Lundahl ;

Urbaneja, Patricia ;

Brichette-Mieg, Isabel ;

Reyes, Virginia ;

Rodriguez-Bada, Jose Luis ;

Alvarez-Lafuente, Roberto ;

Arroyo, Rafael ;

Quintana, Ester ;

Ramio-Torrenta, Lluis ;

Alonso, Ana ;

Leyva, Laura ;

Fernandez, Oscar ;

Oliver-Martos, Begona .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[4] Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database [J].

Allignol, Arthur ;

Boutmy, Emmanuelle ;

Sabido Espin, Meritxell ;

Marhardt, Kurt ;

Vermersch, Patrick .

FRONTIERS IN NEUROLOGY, 2021, 12

[5] Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy [J].

Almouzain, Lubna ;

Stevenson, Fiona ;

Chard, Declan ;

Rahman, Nur Abdul ;

Hamilton, Fiona .

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (01)

[6]

[Anonymous], Summary of product characteristics - Eflexor

[7]

Arnaud L., 2022, EUR COMM TREATM RES, VEP1079

[8] Environmental risk factors for multiple sclerosis. Part I: The role of infection [J].

Ascherio, Alberto ;

Munger, Kassandra L. .

ANNALS OF NEUROLOGY, 2007, 61 (04) :288-299

[9] Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis [J].

Baker, David ;

Marta, Monica ;

Pryce, Gareth ;

Giovannoni, Gavin ;

Schmierer, Klaus .

EBIOMEDICINE, 2017, 16 :41-50

[10] Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course [J].

Baranzini, Sergio E. ;

iMSMS Consortium .

CELL, 2022, 185 (19) :3467-+

← 1 2 3 4 5 6 7 8 9 10 →